A detailed history of Royal Bank Of Canada transactions in Arcellx, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,990 shares of ACLX stock, worth $333,880. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,990
Previous 4,347 14.79%
Holding current value
$333,880
Previous $239,000 74.06%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$50.91 - $86.61 $32,735 - $55,690
643 Added 14.79%
4,990 $416,000
Q2 2024

Aug 14, 2024

BUY
$49.74 - $66.98 $152,055 - $204,757
3,057 Added 236.98%
4,347 $239,000
Q1 2024

Nov 05, 2024

SELL
$51.85 - $73.49 $158,505 - $224,658
-3,057 Reduced 70.32%
1,290 $89,000
Q1 2024

May 15, 2024

SELL
$51.85 - $73.49 $553,965 - $785,167
-10,684 Reduced 89.23%
1,290 $89,000
Q4 2023

Feb 14, 2024

BUY
$31.75 - $57.99 $222,059 - $405,582
6,994 Added 140.44%
11,974 $664,000
Q3 2023

Nov 14, 2023

BUY
$31.51 - $37.4 $63,650 - $75,548
2,020 Added 68.24%
4,980 $178,000
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $34,637 - $59,094
1,260 Added 74.12%
2,960 $93,000
Q1 2023

May 15, 2023

SELL
$26.92 - $33.94 $44,498 - $56,102
-1,653 Reduced 49.3%
1,700 $52,000
Q4 2022

Feb 14, 2023

BUY
$17.18 - $33.0 $50,801 - $97,581
2,957 Added 746.72%
3,353 $103,000
Q3 2022

Nov 14, 2022

SELL
$16.67 - $22.04 $71,347 - $94,331
-4,280 Reduced 91.53%
396 $8,000
Q2 2022

Aug 15, 2022

BUY
$7.21 - $24.43 $22,473 - $76,148
3,117 Added 199.94%
4,676 $85,000
Q1 2022

May 16, 2022

BUY
$12.97 - $19.14 $20,220 - $29,839
1,559 New
1,559 $22,000

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $2.93B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.